Naturex Acquires Licensing Rights for Aronox Aronia Extract

Naturex (Avignon, France) has signed a cooperation licensing agreement with Adamed Consumer Healthcare SA (Pienkow, Poland) for exclusive global rights of its Aronox aronia extract.

 Also known as black chokeberry, aronia, and Aronox in particular, has shown promise for decreasing oxidative stress, reducing cardiovascular risk factors, and improving blood flow in human clinical studies conducted since 2005, says Naturex. Other recent research on aronia has suggested potential positive effects on vision, muscle oxygenation and recovery, and cognitive performance.

“Aronox’s addition to the Naturex portfolio of new botanical extracts with a clinical dossier will enable the group to expand its market presence and strengthen its position in the development and sales of technical solutions with value-added offerings for its customers,” according to a statement from Naturex.

The licensing agreement gives Naturex the global exclusive rights to use the Aronox clinical dossier and trademark, as well as to sublicense Aronox to its customers in all territories where the trademark has been registered. The agreement excluded four Eastern European countries and Spain.

“This partnership with Adamed is part of Ingenium, our new open innovation program,” said Marc Roller, Chief Scientific Officer, Naturex. “Aronox will further enhance our global leadership position in the phytoactives market segment, one of four key categories highlighted in our Bright 2020 strategic plan, with various applications that will help our customers reduce time to market, fitting perfectly with consumers’ expectations.”

Read more:

Naturex, Mazza Sign Agreement for Cranberry Extraction Process

Black Chokeberries Are Returning to North America

National Institutes for Health: A Sneak Peek at Upcoming Dietary Supplement Research Studies